ENDO INTERNATIONAL PLC (NASDAQ:ENDP) Files An 8-K Other Events
Item 8.01.Other Events.

On July 6, 2017, Endo International plc (the “Company”) issued a press release announcing that after careful consideration and consultation with the FDA following the FDA’s June 2017 withdrawal request, the Company has decided to voluntarily remove OPANA^® ER (oxymorphone hydrochloride extended release) from the market. The Company plans to work with the FDA to coordinate an orderly withdrawal of the product from the market. A copy of the Company’s press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.

As a result of the withdrawal of OPANA^® ER from the market, the Company expects to record a pre-tax impairment charge of approximately $20 million to write-off the remaining net book value of its intangible assets associated with OPANA^® ER. The Company will finalize its analysis and record the impairment charge in connection with its second quarter 2017 financial reporting close. Reported net sales of OPANA^® ER were $158.9 million for full-year 2016 and $35.7 million for first quarter 2017.

Item 8.01.Financial Statements and Exhibits.

(d)Exhibits.

Endo International plc Exhibit
EX-99.1 2 opanapr.htm EXHIBIT 99.1 OPANA PR OpanaPR Exhibit 99.1ENDO PROVIDES UPDATE ON OPANA® ERDUBLIN,…
To view the full exhibit click here